Logo Logo Logo Logo Logo
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • Odylia Impact Report
    • Rare Disease Awareness Events
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
      • NPHP1 Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • Odylia Impact Report
    • Rare Disease Awareness Events
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
      • NPHP1 Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
Wendy Erler
Odylia Therapeutics Welcomes Wendy Erler to Board of Directors

Odylia Therapeutics is pleased to announce the appointment of Joy Cavagnaro to its Board of Directors....

22 April, 2026
Services
  • Odylia Pipeline & Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • The Odylia Library
  • The Odylia Collective
  • Resources
  • Webinars and Presentations
  • Clinical Trials
Latest News
  • Odylia Therapeutics Welcomes Wendy Erler to Board of Directors
  • Comend and Odylia Partner to Advance Rare Disease Drug Development with Innovative Patient-Driven Platform
  • Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy
Odylia Therapeutics logo

© 2025 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs